Trial · NCT02338973
Registered outcomes31
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 31
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number and Severity of IP-related AEs | Study duration, up to 52 weeks | The number and severity of adverse events related to the investigation product (IP). |
| Primary | Number of Participants Who Withdrew | Study duration, up to 52 weeks | The number of participants who withdrew early. |
| Secondary | Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1 | Day 1 | Change in BCVA from baseline as compared to Day 1 by participant in both study and fellow eyes. |
| Secondary | Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2 | Day 2 | Change in BCVA from baseline as compared to Day 2 by participant in both study and fellow eyes. |
| Secondary | Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3 | Day 3 | Change in BCVA from baseline as compared to Day 3 by participant in both study and fellow eyes. |
| Secondary | Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2 | Week 2 | Change in BCVA from baseline as compared to Week 2 by participant in both study and fellow eyes. |
| Secondary | Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5 | Week 5 | Change in BCVA from baseline as compared to Week 5 by participant in both study and fellow eyes. |
| Secondary | Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8 | Week 8 | Change in BCVA from baseline as compared to Week 8 by participant in both study and fellow eyes. |
| Secondary | Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52 | Week 52 | Change in BCVA from baseline as compared to Week 52 by participant in both study and fellow eyes. |
| Secondary | Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1 | Day 1 | Change in maximum subretinal fluid volume as measured on OCT from baseline as compared to Day 1 by participant in both study and fellow eyes. |
| Secondary | Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2 | Day 2 | Change in maximum subretinal fluid volume as measured on OCT from baseline as compared to Day 2 by participant in both study and fellow eyes. |
| Secondary | Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3 | Day 3 | Change in maximum subretinal fluid volume as measured on OCT from baseline as compared to Day 3 by participant in both study and fellow eyes. |
| Secondary | Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2 | Week 2 | Change in maximum subretinal fluid volume as measured on OCT from baseline as compared to Week 2 by participant in both study and fellow eyes. |
| Secondary | Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5 | Week 5 | Change in maximum subretinal fluid volume as measured on OCT from baseline as compared to Week 5 by participant in both study and fellow eyes. |
| Secondary | Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8 | Week 8 | Change in maximum subretinal fluid volume as measured on OCT from baseline as compared to Week 8 by participant in both study and fellow eyes. |
| Secondary | Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52 | Week 52 | Change in maximum subretinal fluid volume as measured on OCT from baseline as compared to Week 52 by participant in both study and fellow eyes. |
| Secondary | Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1 | Day 1 | Change in central retinal thickness as measured on Cirrus OCT from baseline as compared to Day 1 by participant in both study and fellow eyes. |
| Secondary | Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2 | Day 2 | Change in central retinal thickness as measured on Cirrus OCT from baseline as compared to Day 2 by participant in both study and fellow eyes. |
| Secondary | Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3 | Day 3 | Change in central retinal thickness as measured on Cirrus OCT from baseline as compared to Day 3 by participant in both study and fellow eyes. |
| Secondary | Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2 | Week 2 | Change in central retinal thickness as measured on Cirrus OCT from baseline as compared to Week 2 by participant in both study and fellow eyes. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02338973/registered